Exact Mass: 312.1968
Exact Mass Matches: 312.1968
Found 106 metabolites which its exact mass value is equals to given mass value 312.1968,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Oseltamivir
Oseltamivir is only found in individuals that have used or taken this drug. It is an acetamido cyclohexene that is a structural homolog of sialic acid and inhibits neuraminidase. [PubChem]Oseltamivir is an ethyl ester prodrug requiring ester hydrolysis for conversion to the active form, oseltamivir carboxylate. The proposed mechanism of action of oseltamivir is inhibition of influenza virus neuraminidase with the possibility of alteration of virus particle aggregation and release. J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AH - Neuraminidase inhibitors COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D000890 - Anti-Infective Agents > D000998 - Antiviral Agents C254 - Anti-Infective Agent > C281 - Antiviral Agent CONFIDENCE standard compound; EAWAG_UCHEM_ID 658 CONFIDENCE standard compound; INTERNAL_ID 2068 D004791 - Enzyme Inhibitors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Granisetron
Granisetron is only found in individuals that have used or taken this drug. It is a serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. [PubChem]Granisetron is a potent, selective antagonist of 5-HT3 receptors. The antiemetic activity of the drug is brought about through the inhibition of 5-HT3 receptors present both centrally (medullary chemoreceptor zone) and peripherally (GI tract). This inhibition of 5-HT3 receptors in turn inhibits the visceral afferent stimulation of the vomiting center, likely indirectly at the level of the area postrema, as well as through direct inhibition of serotonin activity within the area postrema and the chemoreceptor trigger zone. A - Alimentary tract and metabolism > A04 - Antiemetics and antinauseants > A04A - Antiemetics and antinauseants > A04AA - Serotonin (5ht3) antagonists C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist > C94726 - 5-HT3 Receptor Antagonist D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents C78272 - Agent Affecting Nervous System > C267 - Antiemetic Agent D005765 - Gastrointestinal Agents > D000932 - Antiemetics D002491 - Central Nervous System Agents Granisetron (BRL 43694) is a serotonin 5-HT3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy.
(±)-2,4,6-Triphenyl-1-hexene
Styrene trimer. Present as an impurity in polystyrene food containers and other products - liberated on heating. Styrene trimer. Present as an impurity in polystyrene food containers and other products - liberated on heating
1,3,5-Triphenylcyclohexane
1,3,5-Triphenylcyclohexane is a packaging migration residue. Present as an impurity in polystyrene food containers and other products; liberated on heating. Packaging migration residue. Present as an impurity in polystyrene food containers and other products; liberated on heating
1,2,3,4-Tetrahydro-1-phenyl-4-(2-phenylethyl)naphthalene
1,2,3,4-Tetrahydro-1-phenyl-4-(2-phenylethyl)naphthalene is a packaging migration residue. Packaging migration residue
1,2,3,4-Tetrahydro-1-phenyl-4-(1-phenylethyl)naphthalene
1,2,3,4-Tetrahydro-1-phenyl-4-(1-phenylethyl)naphthalene is a packaging migration residue. Packaging migration residue
4beta-acetoxy-9beta,10beta,15alpha-trihydroxyprobotrydial
(1S*,6R*,7S*,8S*,11R*)-6,11-diphenyltricyclo[6.2.2.02,7]dodeca-2,9-diene
(3S,6S)-3-acetoxy-2,2,6-trimethyl-6-([1S,4R]-4-hydroperoxy-4-methylcyclohex-2-en-1-yl)tetrahydropyran
(2S,3R,4S,4aR,7S,7aS,3R,5R,Z)-2-(3,5-dimethylhept-1-enyl)-3,4-dihydroxy-7-methyl-4,4a,7,7a-tetrahydro-2H-furo[3,4-b]pyran-5(3H)-one|fusidilactone E
Me ester-(+_)-2,5-Dihydro-2-methoxy-3,4-dimethyl-5-oxo-2-furannonanoic acid
Artemotil
Artemotil is an artemisinin derivative. Artemotil, also known as β-arteether, is a semi-synthetic derivative of artemisinin and a fast acting blood schizonticide specifically indicated for the treatment of chloroquine-resistant Plasmodium falciparum malaria and cerebral malaria cases. P - Antiparasitic products, insecticides and repellents > P01 - Antiprotozoals > P01B - Antimalarials > P01BE - Artemisinin and derivatives, plain D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000871 - Anthelmintics C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C277 - Antiprotozoal Agent D009676 - Noxae > D016877 - Oxidants > D010545 - Peroxides Artemotil (β-Arteether) has antimalarial activity for the treatment of chloroquine-resistant Plasmodium falciparum malaria with an IC50 of 1.61 nM. Artemotil also has central nervous system (CNS) neurotoxicity and anorectic toxicity in rats, dogs and monkeys[1][2]. Artemotil (β-Arteether) has antimalarial activity for the treatment of chloroquine-resistant Plasmodium falciparum malaria with an IC50 of 1.61 nM. Artemotil also has central nervous system (CNS) neurotoxicity and anorectic toxicity in rats, dogs and monkeys[1][2].
Oseltamivir
A cyclohexenecarboxylate ester that is the ethyl ester of oseltamivir acid. An antiviral prodrug (it is hydrolysed to the active free carboxylic acid in the liver), it is used to slow the spread of influenza. J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AH - Neuraminidase inhibitors COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D000890 - Anti-Infective Agents > D000998 - Antiviral Agents C254 - Anti-Infective Agent > C281 - Antiviral Agent D004791 - Enzyme Inhibitors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Disclaimer: While authors make an effort to ensure that the content of this record is accurate, the authors make no representations or warranties in relation to the accuracy or completeness of the record. This record do not reflect any viewpoints of the affiliation and organization to which the authors belong.
granisetron
A - Alimentary tract and metabolism > A04 - Antiemetics and antinauseants > A04A - Antiemetics and antinauseants > A04AA - Serotonin (5ht3) antagonists C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist > C94726 - 5-HT3 Receptor Antagonist D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents C78272 - Agent Affecting Nervous System > C267 - Antiemetic Agent D005765 - Gastrointestinal Agents > D000932 - Antiemetics D002491 - Central Nervous System Agents Granisetron (BRL 43694) is a serotonin 5-HT3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy.
FA 17:3;O3
4-[(2,6-Diisopropylphenoxy)methyl]phenylboronic acid
2-[(2,6-Diisopropylphenoxy)methyl]phenylboronic acid
(2-n-benzylaminoethyl)-3-aminopropyl-trimethoxysilane,tech-90
2-Methyl-2-propanyl 4-[(2S)-2-(methoxycarbonyl)-1-pyrrolidinyl]-1 -piperidinecarboxylate
1-(TERT-BUTOXYCARBONYL)-[1,4-BIPIPERIDINE]-4-CARBOXYLIC ACID
N,N,N,N-TETRAMETHYL-N-[TRIS(DIMETHYLAMINO)PHOSPHORANYLIDENE]PHOSPHORIC TRIAMIDE
Granisetronum
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents D005765 - Gastrointestinal Agents > D000932 - Antiemetics D002491 - Central Nervous System Agents
Etidocaine hydrochloride
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D000777 - Anesthetics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C245 - Anesthetic Agent
1-methyl-N-[(1S,5S)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]-3-indazolecarboxamide
(3,5-dimethylphenyl)[4-(3-ethyl-4H-1,2,4-triazol-4-yl)piperidino]methanone
2-[(3R,6aS,8R,10aS)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide
2-[(3R,6aS,8S,10aS)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide
2-[(3S,6aR,8S,10aR)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide
2-[(3R,6aR,8S,10aR)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide
2-[(3S,6aS,8S,10aS)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide
2-[(3R,6aR,8R,10aR)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide
2-[(3S,6aR,8R,10aR)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide
2-[(3S,6aS,8R,10aS)-3-hydroxy-1-methyl-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-cyclobutylacetamide
(3S,4S)-5-Benzyloxy-3-(2-methoxyethoxymethoxy)-4-methylpentan-2-ol
1,2,3,4-Tetrahydro-1-phenyl-4-(1-phenylethyl)naphthalene
1-phenyl-4-(2-phenylethyl)-1,2,3,4-tetrahydronaphthalene
(7Z)-14-hydroxy-10,13-dioxoheptadec-7-enoic acid
A monounsaturated fatty acid that is (7Z)-heptadec-7-enoic acid which is substituted by a hydroxy group at position 14 and by oxo groups at positions 10 and 13.
(2r)-2,3-dihydroxypropyl (2e,4e,8e,13s)-13-hydroxytetradeca-2,4,8-trienoate
2,3,11-trihydroxy-4,6,6,10-tetramethyltricyclo[5.3.1.0⁴,¹¹]undecan-8-yl acetate
(3s,6s)-6-[(1s,4r)-4-hydroperoxy-4-methylcyclohex-2-en-1-yl]-2,2,6-trimethyloxan-3-yl acetate
12-ethyl-4,11-dihydroxy-3,5,7,11-tetramethyl-1-oxacyclododec-9-ene-2,8-dione
6-(4-hydroperoxy-4-methylcyclohex-2-en-1-yl)-2,2,6-trimethyloxan-3-yl acetate
(9e)-12-ethyl-4,11-dihydroxy-3,5,7,11-tetramethyl-1-oxacyclododec-9-ene-2,8-dione
2-(3,5-dimethylhept-1-en-1-yl)-3,4-dihydroxy-7-methyl-hexahydrofuro[3,4-b]pyran-5-one
2-(3,4,8-trihydroxy-3,8-dimethyl-octahydroazulen-5-yl)prop-2-en-1-yl acetate
4β- Acetoxy- 9β,10β,15α-trihydroxyp robotrydial
{"Ingredient_id": "HBIN010263","Ingredient_name": "4\u03b2- Acetoxy- 9\u03b2,10\u03b2,15\u03b1-trihydroxyp robotrydial","Alias": "NA","Ingredient_formula": "C17H28O5","Ingredient_Smile": "CC1CC(C2C(CC3(C2(C1C(C3O)O)O)C)(C)C)OC(=O)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "42940","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
